300
Participants
Start Date
August 21, 2025
Primary Completion Date
January 31, 2030
Study Completion Date
January 31, 2030
Non-Metastatic and Resectable
"Blood Draw Timepoints:~* Before any treatment begins~* After Neo-adjuvant therapy (only if you receive this type of therapy)~* After local surgery~* After Adjuvant therapy (only if you receive this type of therapy)~* Follow up after adjuvant therapy: at Months 3, 6, 9, 12, 15, 18, and 24~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
Metastatic and Un-resectable
"Blood Draw Timepoints:~* Before any treatment begins~* During standard of care disease evaluation visits for up to 24 months"
No evidence of disease, under surveillance
"Blood Draw Timepoints:~* From completion of treatment- at Months 3, 6, 9, 12, 15, 18, and 24; depending on when you enroll into the study you will start at the next timepoint in this schedule~* After evidence of recurrence or worsening of disease, and then collected at standard of care disease evaluation visits up until 24 months from the last treatment for the initial diagnosis"
ALT or WDLS
"Blood Draw Timepoints:~• Collect once after surgery (up to six weeks after surgery)"
RECRUITING
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RECRUITING
Levine Cancer Institute, Charlotte
Paula Takacs Foundation
UNKNOWN
Wake Forest University Health Sciences
OTHER